Angiodynamics (ANGO) Gross Profit (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Gross Profit data on file, last reported at $41.5 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 6.75% year-over-year to $41.5 million; the trailing twelve-month figure through Feb 2026 stood at $170.3 million (up 10.61% YoY), and the FY2025 full-year result was $157.7 million, up 1.94% from the prior year.
• Gross Profit for Q1 2026 stood at $41.5 million, down from $44.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $46.5 million in Q2 2022 and bottomed at $35.9 million in Q1 2024.
• The 5-year median for Gross Profit is $40.5 million (2023), against an average of $41.2 million.
• The widest annual swing landed in 2024, when Gross Profit declined 16.92%; it then grew 13.98% in 2025.
• A 5-year view of Gross Profit shows it stood at $45.1 million in 2022, then decreased by 10.68% to $40.3 million in 2023, then dropped by 0.88% to $39.9 million in 2024, then rose by 12.22% to $44.8 million in 2025, then declined by 7.38% to $41.5 million in 2026.
• The last three Gross Profit figures came in at $41.5 million (Q1 2026), $44.8 million (Q4 2025), and $41.9 million (Q3 2025), per Business Quant data.

Peer Comparison